Data protection Impressum

Personalized Medicine

Vaud-based biopharma Oculis has successfully completed an oversubscribed USD 100 million offering, further strengthening its pipeline of innovative ophthalmic and neuro-ophthalmic treatments.

Oculis secures USD 100 million to advance its neuroprotective treatment pipeline

17 February 2025

The University Hospitals of Geneva (HUG) have introduced Switzerland’s first AI-driven medical chatbot, “confIAnce”, providing reliable, verified general medical information. This innovation represents a major step in integrating artificial intelligence into Swiss healthcare.

HUG pioneers AI-powered healthcare with Switzerland’s first medical chatbot

10 February 2025

The Lausanne University Hospital (CHUV) has secured market authorization from Swissmedic to produce a fecal microbiota transplant (FMT) medication, making it the first accredited center in Switzerland to manufacture this treatment under strict pharmaceutical standards. This breakthrough provides an effective solution for patients suffering from recurrent Clostridioides difficile infections, a debilitating condition characterized by repeated digestive blowouts and severe discomfort.

CHUV becomes first Swiss hospital to produce gut-balancing medication

29 January 2025

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

Fribourg-based digital health start-up Neuria, a spin-off from the University of Fribourg, is set to launch its patented brain recalibration platform in Switzerland and the US.

Fribourg’s Neuria prepares to launch its brain recalibration platform

13 January 2025

Vanarix, a Biopôle-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its bioengineered cartilage mini-implants, Cartibeads.

Vanarix secures FDA Orphan Drug designation for its Cartibeads

7 January 2025

Vandria, a Lausanne-based biotech pioneer in mitochondrial therapeutics, has dosed the first participants in a Phase 1 clinical trial for its lead compound, VNA-318, marking a critical step toward addressing neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Vandria begins clinical trials for Alzheimer’s drug VNA-318

7 January 2025

ONWARD Medical has achieved a significant milestone with FDA de novo classification and market authorization for its non-invasive ARC-EX System, the first technology approved to enhance hand strength and sensation after chronic spinal cord injury.

ONWARD Medical receives FDA authorization for its spinal cord stimulation system

6 January 2025

Spirecut, a Swiss medtech pioneer in ultrasound-guided hand surgery, has inaugurated Switzerland’s first Center of Excellence at the Clinique de la Main in Geneva. The center aims to train surgeons in the SonoSurgery technique while supporting research into new applications for Spirecut’s Sono-Instruments®.

Spirecut opens Switzerland’s first Center of Excellence for ultrasound-guided hand surgery

17 December 2024

1 2 3 4 5 … 16